 |
|
|
| |
Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) for the Treatment of
People Living With HIV: 24-Month Analyses by Age, Race, Sex, Adherence and
Late Diagnosis in a Multi-Country Cohort Study
|
| |
| |
Benoit Trottier,1* Andrea Antinori,2 Joss De Wet,3 Claudine Duvivier,4,5 Hila Elinav,6 Stefan Esser,7 Jade Ghosn,8 Jan den Hollander,9 John S Lambert,10,11 Ana Milinkovic,12 Cindy Elliott,13
Taban Saifi,14 Richard Haubrich,15 David Thorpe,16 Andrea Marongiu,16 Celia Miralles,17 Sven Schellberg,18 Berend van Welzen19
1. Clinique de Médecine Urbaine du Quartier Latin, Montreal, QC, Canada; 2. National Institute of Infectious Diseases, L. Spallanzani, IRCCS, Rome, Italy; 3. Spectrum Health, Vancouver, BC, Canada; 4. AP-HP - Necker-Enfants Malades Hospital, Infectious Diseases Department, Necker-Pasteur Infectiology Center, IHU Imagine, Paris, France; 5. Institut Cochin - CNRS 8104 - INSERM U1016 - RIL (Retrovirus, Infection and Latency) Team, University of Paris, Paris, France; 6. Hadassah Hebrew University Medical Center, Jerusalem, Israel; 7. University Hospital Essen, Essen, Germany; 8. Bichat University Hospital, Paris, France; 9. Maasstad Hospital, Rotterdam, the Netherlands; 10. Mater Misericordiae University Hospital, Dublin, Ireland; 11. University College Dublin, Dublin, Ireland; 12. Chelsea and Westminster Hospital, London, UK; 13. Gilead Sciences Ltd, London, UK; 14. Gilead Sciences Inc., Mississauga, ON, Canada;
15. Gilead Sciences, Inc., Foster City, CA, USA; 16. Gilead Sciences Ltd, Stockley Park, UK; 17. Complexo Hospitalario Universitario de Vigo, Vigo, Spain; 18. Novopraxis Berlin GbR, Berlin, Germany; 19. University Medical Centre Utrecht, Utrecht, the Netherlands
*bentrotte@gmail.com
|
| |
|
|
|
|
|
